Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

10 p | 2 | 2